Persistent neuropathy and hyperkeratosis from distant arsenic exposure

Journal of Agromedicine

Volumn 10, Issue 4, 2005, Pages 43-54

  Baker, Beth A ^a   Topliff, Andrew R ^b   Messing, Rita B ^c   Durkin, Deborah ^c   Johnson, Jean Small ^c  

^a Regions Medical Center   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

Arsenic; Hyperkeratosis; Neuropathy; Polyneuropathy

Indexed keywords

ARSENIC;

ADULT; ARSENIC POISONING; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG EFFECT; FATALITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; NERVE CONDUCTION; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; SKIN DISEASE; WATER SUPPLY;

ADULT; ARSENIC; ARSENIC POISONING; COHORT STUDIES; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; SKIN DISEASES; WATER SUPPLY;

EID: 33747385026     PISSN: 1059924X     EISSN: 15450813     Source Type: Journal    
DOI: 10.1300/J096v10n04_07     Document Type: Article

References (59)

1. Feinglass EJ. Arsenic intoxication from well water in the United States. N Engl J Med. 1973 Apr 19;288 (16):828-30.
2. Landrigan PJ. Arsenic-state of the art. Am J Ind Med. 1981;2(1):5-14.
3. Chhuttani PN, Chawla LS, Sharma TD. Arsenical neuropathy. Neurology. 1967 Mar;17:269-74.
4. Gerr F, Letz R, Ryan PB, Green RC. Neurological effects of environmental exposure to arsenic in dust and soil among humans. Neurotoxicology. 2000 Aug;21(4); 475-87.
5. Blom S, Lagerkvist B, Linderholm H. Arsenic exposure to smelter workers.Clinical and neurophysiological studies. Scand J Work Environ Health. 1985 Aug;11 (4):265-9.
6. Heyman A, Pfeiffer JB Jr, Willett RW, Taylor HM. Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2,3 dimercapto-propanol). N Engl J Med. 1956 Mar 1;254(9):401-9.
7. Feldman RG, Niles CA, Kelly-Hayes M, Sax DS, Dixon WJ,Thompson DJ, Landau E. Peripheral neuropathy in arsenic smelter workers. Neurology. 1979 Jul;29 (7):939-44.
8. Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to arsenic. Clinical course in four patients with electrophysiological and histological studies. J Neurol Sci. 1977 Jul;32(3):437-51.
9. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect. 1999 May;107(5):359-65.
10. Mukherjee SC, Rahman MM, Chowdhury UK, Sengupta MK, Lodh D, Chanda CR, Saha KC, Chakraborti D. Neuropathy in arsenic toxicity from groundwater arsenic contamination in West Bengal, India. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003;A38(1): 165-83.
11. Mazumder DN. Chronic Arsenic Toxicity: Clinical Features, Epidemiology, and Treatment: Experience in West Bengal; J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003;A38(1):141-63.
12. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J 2003 Jul;79(933):391-6. Review.
13. Rahman MM, Sengupta MR, Ahamed S, Chowdhury UK, Hossain MA, Das B, Iodh D, Saha KC, Pati S, Kaies I, Barua AK, Chakraborti D. The magnitude of arsenic contamination in groundwater and its health effects to the inhabitants of the Jalangi-one of the 85 arsenic affected blocks in West Bengal, India. Sci Total Environ. 2005 Feb;338(3):189-200.
14. Mead MN. Arsenic: In search of an antidote to a global poison. Environ Health Perspect. 2005 Jun;113 (6):A378-86.
15. Chowdhury UK, Biswas BK, Chowdhury TR, Samanta G, Mandal BK, Basu GC, Chanda CR, Lodh D, Saha KC, Mukherjee SK, Roy S, Kabir S, Quamruzzaman Q, Chakraborti D. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect. 2000 May;108(5):393-7.
16. Sengupta MK, Mukherjee A, Hossain MA, Ahamed S, Rahman MM, Lodh D, Chowdhury UK, Biswas BK, Nayak B, Das B, Saha KC, Chakraborti D, Mukherjee SC, Chatterjee G, Pati S, Dutta RN, Quamruzzaman Q. Groundwater arsenic contamination in the Ganga-Padma-Meghna-Brahmaputra plain of India and Bangladesh. Arch Environ Health. 2003 Nov;58(11):701-2.
17. Samanta G, Sharma R, Roychowdhury T,Chakraborti D. Arsenic and other elements in hair, nails, and skinscales of arsenic victims in West Bengal, India. Sci Total Environ. 2004 Jun 29;326(1-3):33-47.
18. Mandal BK, Ogra Y, Anzai K, Suzuki KT. Speciation of arsenic in biological samples. Toxicol Appl Pharmacol. 2004 Aug 1;198(3):307-18.
19. Hall AH. Chronic arsenic poisoning. Toxicol Lett. 2002 Mar 10;128(1-3):69-72. Review.
20. Annex 4, Chemical Summary Tables. In: Guidelines for drinking-water quality. Vol 1, 3rd ed. World Health Organization; 2004 [cited 2005 Sep 9]. Available from: http://www.who.int/water_sanitation_health/dwq/en/ gdwq3_ann4tab.pdf.
21. Graeme KA, Pollack CV Jr. Heavy metal toxicity, Part 1: Arsenic and mercury. J Emerg Med. 1998 Jan-Feb;16(1):45-56. Review.
22. Winship KA. Toxicity of inorganic arsenic salts. Adverse Drug React Acute Poisoning Rev. 1984 Autumn; 3(3):129-60. Review.
23. Franzblau A, Lilis R. Acute arsenic intoxication from environmental arsenic exposure. Arch Environ Health. 1989 Nov-Dec;44(6):385-90.
24. Hindmarsh JT. Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem. 2002 Feb;35(1):1-11. Review.
25. Lagerkvist BJ, Zetterlund B. Assessment of exposure to arsenic among smelter workers: A five year follow-up. Am J Ind Med. 1994 Apr;25(4):477-88.
26. Hindmarsh JT, MeLetchie OR, Hefferman LPM, Hayne OA, Ellenberger HA, McCurdy RF, Thiebaux HJ. Electromyographic abnormalities in chronic environmental arsenicalism. J Anal Toxicol.1977;1:270-6.
27. Murphy MJ, Lyon LW, Taylor JW. Subacute arsenic neuropathy; clinical and electrophysiological observations. J Neurol Neurosurg Psychiatry. 1981 Oct;44 (10):896-900.
28. Oh, SJ. Electrophysiological profile in arsenic neuropathy. J Neurol Neurosurg Psychiatry. 1991 Dec;54 (12)1103-5.
29. Ford MD. Arsenic. In: Goldfrank L,editor. Goldfrank's Toxicologic Emergencies. 7th ed. New York: McGraw-Hill; 2002. p. 1183-1200.
30. Saha KC. Diagnosis of arsenicosis. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan; A38(1):255-72. Review.
31. Minnesota Pollution Control Agency (MPCA). Perham Arsenic Site Remedy. St. Paul (MN): Minnesota Pollution Control Agency; 1996.
32. Dotson RM. Clinical neurophysiology laboratory tests to assess the nociceptive system in humans. J Clin Neurophysiol. 1997 Jan;14(1):32-45. Review.
33. Katims JJ. Electrodiagnostic functional sensory evaluation of the patient with pain: A review of the neuroselective current perception threshold (CPT) and pain tolerance threshold (PTT). Pain Digest. 1998;8(5): 219-230.
34. Ro LS, Chen ST, Tang LM, Hsu WC, Chang HS, Huang CC. Current perception threshold testing in Fabry's disease. Muscle Nerve. 1999 Nov;22(11):1531-7.
35. Katims JJ, Long DM, Ng LK. Transcutaneous nerve stimulation (TNS). Frequency and waveform specificity in humans. Appl Neurophysiol. 1986;49(1-2): 86-91.
36. Katims JJ, Naviasky EH, Rendell MS, Ng LK, Bleecker ML. Constant current sine wave transcutaneous nerve stimulation for the evaluation of peripheral neuropathy. Arch Phys Med Rehabil. 1987 Apr;68(4):210-3.
37. Lengyel C, Torok T, Varkonyi T, Kempler P, Rudas L. Baroreflex sensitivity and heart rate variability in insulin-dependent diabetics with polyneuropathy. Lancet. 1998 May 9;351(9113);1436-7.
38. Cheng WY, Jiang YD, Chuang LM, Huang CN, Heng LT, Wu HP, Tai TY, Lin BJ. Quantitative sensory testing and risk factors of diabetic sensory neuropathy. J Neurol. 1999 May;246(5):394-8.
39. Bleecker ML, Lindgren KN, Tiburzi MJ, Ford DP. Curvilinear relationship between blood lead level and reaction time. J Occup Environ Med. 1997 May;39(5): 426-31.
40. Bleecker ML, Ford DP, Tiburzi MJ, Lindgren KN. The relationship between peripheral nerve function and markers of lead dose. Neurology. 1998 April;50(4),(4 Suppl);A53.
41. Shields M, Beckmann SL, Cassidy-Brinn G. Improvement in Perception of Transcutaneous Nerve Stimulation Following Detoxification in Firefighters Exposed to PCBs, PCDDs and PCDFs. Clinical Ecology 1989; 6(2);47-50.
42. New P. Neuroselective current perception threshold quantitative sensory test: A reevaluation. Neurology. 1997 Nov;49(5);1482.
43. Husin LS, Uttaman A, Hirsham HJ, Hussain IH, Jamil MR. The effect of pesticide on the activity of serum cholinesterase and current perception threshold on the paddy farmers in Muda agricultural development area, MADA, Kedah, Malaysia. Med J Malaysia; 1999 Sep; 54(3);320-4.
44. Palliyath S, Preyan S: The role of Current Perception Threshold (CPT) in Evaluating Peripheral Neuropathy. Accepted for presentation at the XVIth World Congress of Neurology, Buenos Aires, Argentina, 1997.
45. Berger JS, Brannagan TH, Latov N. Neuropathy with anti-myelin-associated glycoprotein antibodies; quantitative sensory testing and response to intravenous immunoglobulin; 44th annual Meeting of the American Association of Electrodiagnostic Medicine 71, 1997.
46. Katims JJ, Naviasky EH, Ng LK, Rendell M, Bleecker ML. New screening device for assessment of peripheral neuropathy. J Occup Med. 1986 Dec;28(12); 1219-21.
47. Katims JJ, Rouvelas P, Sadler BT, Weseley SA. Current perception threshold: Reproducibility and comparison with nerve conduction in evaluation of carpal tunnel syndrome. ASAIO Trans. 1989 Jul-Sep;35(3): 280-4.
48. Barkai L, Kempler P, Vamosi I, Lukacs K, Marton A, Keresztes K. Peripheral sensory nerve dysfunction in children and adolescents with type I diabetes mellitus. Diabet Med. 1998 Mar;15(3):228-33.
49. Umezawa S, Kananori A, Yajima Y, Aoki C. Current perception threshold in evaluating diabetic neuropathy. Journal of the Japanese Diabetes Society. 1997; 8(1):711-19.
50. Kurozawa Y, Nasu Y. Current perception thresholds in vibration-induced neuropathy. Arch Environ Health. 2001 May-Jun;56(3):254-6.
51. SNCT/CPT testing® CPT/C Operating Manual. Neurotron, Inc. Baltimore (MD); 1999.
52. Katims JJ, Naviasky EH, Ng LK, Rendell M, Bleecker ML. New screening device for assessment of peripheral neuropathy. J Occup Med. 1986 Dec; 28(12); 1219-21.
53. Takekuma K, Ando F, Niino N, Shimokata H. Age and gender differences in skin sensory threshold assessed by current perception in community-dwelling Japanese. J Epidemiol. 2000 Apr;10(1 Suppl):S33-S38.
54. Wax PM, Thornton CA. Recovery from severe arsenic-induced peripheral neuropathy with 2,3-dimercapto-1-propanesulphonic acid. J Toxicol Clin Toxicol. 2000; 38(7):777-80.
55. Kurttio P, Komulainen H, Hakala E, Kahelin H, Pekkanen J. Urinary excretion of arsenic species after exposure to arsenic present in drinking water. Arch Environ Contam Toxicol. 1998 Apr;34(3):297-305.
56. Srivastava AK, Hasan SK, Srivastava RC. Arsenicism in India: Dermal lesions and hair levels. Arch Enviorn Health. 2001 Nov-Dec;56(6):562.
57. Takagi Y, Matsuda S, Imai S, Ohmori Y, Masuda T, Vinson JA, Mehra MC, Puri BK, Kaniewski A. Trace Elements in human hair: An international comparison. Bull Environ Contam Toxicol 1986 Jun;36(6):793-800.
58. Seidel S, Kreutzer R, Smith D, McNeel S, Gilliss D. Assessment of commercial laboratories performing hair mineral analysis. JAMA. 2001 Jan 3;285(1):67-72.
59. Shamberger RJ. Validity of hair mineral testing. Biol Trace Elem Res. 2002 Summer;87(1-3):1-28.